Trial Evaluating Use of Arista in Total Thyroidectomy

Withdrawn before enrolling · Not applicable

Conditions studied: Thyroidectomy, Seroma

In brief

This is a single-blinded randomized controlled trial to evaluate the effectiveness of Arista hemostatic matrix powder (Arista® AH, C. R. Bard, Inc. Davol, Warwick, RI) in reducing drainage output after total thyroidectomy with and without lateral neck dissections. Increased drainage in total thyroidectomy and neck dissection wound beds can lead to seroma formation with possible secondary infection, delayed hospital discharge, and additional home care needs for drain care. Arista is an inert plant based absorbable surgical hemostatic powder that can be easily applied to broad surgical fields to reduce bleeding and seroma rates. Therefore, its application to thyroidectomy and neck dissection wound beds may bear significant potential benefit.

Key facts

Study ID

NCT02568085

Run by

University of California, San Francisco

People needed

0

Starts

2016-03-01

Expected to finish

2017-06-01

Last updated by the study team

2019-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing Total Thyroidectomy with or without lateral neck dissection
• Patient must be 18 years of age or older.
• The patient must have capacity to be able to sign a study-specific informed consent prior to study

You may not qualify if…

• Pregnancy (for female patients).
• Patients who will require anticoagulant medications other than routine DVT prophylaxis within 8 days postoperatively.
• Presence of clotting or bleeding disorder.

Where it is running

• UCSF Mission Bay — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.